Moderna (MRNA) Competitors

Robinhood Markets has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Robinhood Markets, indicating that it is currently the more affordable of the two stocks.

Moderna currently has a consensus target price of $80.53, suggesting a potential downside of 41.64%. Robinhood Markets has a consensus target price of $120.52, suggesting a potential upside of 15.60%. Given Robinhood Markets' stronger consensus rating and higher probable upside, analysts clearly believe Robinhood Markets is more favorable than Moderna.

In the previous week, Moderna had 45 more articles in the media than Robinhood Markets. MarketBeat recorded 82 mentions for Moderna and 37 mentions for Robinhood Markets. Robinhood Markets' average media sentiment score of 0.63 beat Moderna's score of 0.41 indicating that Robinhood Markets is being referred to more favorably in the news media.

Moderna has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Robinhood Markets has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 93.3% of Robinhood Markets shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 13.5% of Robinhood Markets shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Robinhood Markets has a net margin of 42.01% compared to Moderna's net margin of -141.43%. Robinhood Markets' return on equity of 22.43% beat Moderna's return on equity.

In the previous week, Moderna had 52 more articles in the media than Novavax. MarketBeat recorded 82 mentions for Moderna and 30 mentions for Novavax. Moderna's average media sentiment score of 0.41 beat Novavax's score of 0.15 indicating that Moderna is being referred to more favorably in the news media.

Novavax has a beta of 2.46, meaning that its share price is 146% more volatile than the broader market. Comparatively, Moderna has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

53.0% of Novavax shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Novavax has a net margin of -59.87% compared to Moderna's net margin of -141.43%. Novavax's return on equity of -14.82% beat Moderna's return on equity.

Novavax has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Novavax currently has a consensus price target of $14.00, indicating a potential upside of 51.19%. Moderna has a consensus price target of $80.53, indicating a potential downside of 41.64%. Given Novavax's stronger consensus rating and higher probable upside, equities research analysts clearly believe Novavax is more favorable than Moderna.

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Ocugen presently has a consensus price target of $9.50, suggesting a potential upside of 619.70%. Moderna has a consensus price target of $80.53, suggesting a potential downside of 41.64%. Given Ocugen's stronger consensus rating and higher probable upside, equities research analysts plainly believe Ocugen is more favorable than Moderna.

In the previous week, Moderna had 77 more articles in the media than Ocugen. MarketBeat recorded 82 mentions for Moderna and 5 mentions for Ocugen. Ocugen's average media sentiment score of 1.07 beat Moderna's score of 0.41 indicating that Ocugen is being referred to more favorably in the media.

Ocugen has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market. Comparatively, Moderna has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

Ocugen has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Ocugen's return on equity.

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 4.0% of Ocugen shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Regeneron Pharmaceuticals presently has a consensus target price of $800.36, indicating a potential upside of 0.78%. Moderna has a consensus target price of $80.53, indicating a potential downside of 41.64%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Moderna.

Regeneron Pharmaceuticals has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, Moderna has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

Regeneron Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Moderna's net margin of -141.43%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Moderna's return on equity.

In the previous week, Moderna had 18 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 82 mentions for Moderna and 64 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.13 beat Moderna's score of 0.41 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.